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Neuropathic MORC2 mutations perturb GHKL
ATPase dimerization dynamics and epigenetic
silencing by multiple structural mechanisms
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Missense mutations in MORC2 cause neuropathies including spinal muscular atrophy and
Charcot–Marie–Tooth disease. We recently identiﬁed MORC2 as an effector of epigenetic
silencing by the human silencing hub (HUSH). Here we report the biochemical and cellular
activities of MORC2 variants, alongside crystal structures of wild-type and neuropathic forms
of a human MORC2 fragment comprising the GHKL-type ATPase module and CW-type zinc
ﬁnger. This fragment dimerizes upon binding ATP and contains a hinged, functionally critical
coiled-coil insertion absent in other GHKL ATPases. We ﬁnd that dimerization and DNA
binding of the MORC2 ATPase module transduce HUSH-dependent silencing. Disease
mutations change the dynamics of dimerization by distinct structural mechanisms: destabi-
lizing the ATPase-CW module, trapping the ATP lid, or perturbing the dimer interface. These
defects lead to the modulation of HUSH function, thus providing a molecular basis for
understanding MORC2-associated neuropathies.
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M icrorchidia CW-type zinc ﬁnger proteins (MORCs) area family of transcriptional regulators conserved ineukaryotes. More speciﬁcally, MORCs regulate the
epigenetic control of transposons and newly integrated transgenes
at different developmental stages in plants1,2, nematodes1,3, and
mammals4,5. Four mammalian genes (MORC1–4) have been
annotated. MORC1 is required for spermatogenesis in mice6, as
an effector of transposon silencing5. We recently showed that
human MORC2 is necessary, in conjunction with the human
silencing hub (HUSH), for silencing of transgenes integrated at
chromatin loci with histone H3 trimethylated at lysine 9
H3K9me34,7. HUSH and MORC2 were further found to restrict
transposable elements from the long interspersed element-1
class8. MORC2 has also been reported to have ATP-dependent
chromatin remodeling activity, which contributes to the DNA
damage response9 and to downregulation of oncogenic carbonic
anhydrase IX in a mechanism dependent on histone deacetylation
by HDAC410. MORC3 localizes to H3K4me3-marked chromatin,
but the biological function of MORC3 remains unknown11.
Despite growing evidence of their importance as chromatin
regulators, MORCs have been sparsely characterized at the
molecular level. Mammalian MORCs are large, multidomain
proteins, with an N-terminal gyrase, heat shock protein 90, his-
tidine kinase and MutL (GHKL)-type ATPase module, a central
CW-type zinc ﬁnger (CW) domain, and a divergent C-terminal
region with one or more coiled coils that are thought to enable
constitutive dimerization12. Structural maintenance of chromo-
somes ﬂexible hinge domain-containing protein 1 (SMCHD1)
shares some of these key features and could therefore be con-
sidered as a ﬁfth mammalian MORC, but it lacks a CW domain,
and has a long central linker connecting to an SMC-like hinge
domain13. As with several other members of the GHKL super-
family, the ATPase module of MORC3 dimerizes in an ATP-
dependent manner11. The recently reported crystal structure of
the ATPase-CW cassette from mouse MORC3 consists of a
homodimer, with the non-hydrolysable ATP analog AMPPNP
and an H3K4me3 peptide fragment bound to each protomer11.
The trimethyl-lysine of the H3K4me3 peptide binds to an aro-
matic cage in the CW domains of MORC3 and MORC411,14,15.
The MORC3 ATPase domain was also shown to bind DNA, and
the CW domain of MORC3 was proposed to autoinhibit DNA
binding and ATP hydrolysis by the ATPase module15. Based on
the observed biochemical activities, MORCs have been proposed
to function as ATP-dependent molecular clamps around DNA11.
However, the CW domains of MORC1 and MORC2 lack the
aromatic cage and do not bind H3K4me3, suggesting that dif-
ferent MORCs engage with chromatin via different mechan-
isms4,14. Moreover, MORC1 and MORC2 contain additional
domains, including a predicted coiled-coil insertion within the
ATPase module that has not been found in any other GHKL
ATPases.
Exome sequencing data from patients with genetically unsolved
neuropathies have recently reported missense mutations in the
ATPase module of the MORC2 gene16–23. A range of symptoms
have been detailed, all subject to autosomal dominant inheritance,
with a complex genotype–phenotype correlation. Several reports
describe Charcot–Marie–Tooth (CMT) disease in families carry-
ing MORC2 mutations including R252W (most commonly)
16,17,20,21; patients presented in the ﬁrst or second decade with
distal weakness that spread proximally, usually accompanied by
signs of CNS involvement. Two other mutations, S87L and
T424R, have been reported to cause congenital or infantile onset
of neuropathies16,19,21,22. Severe spinal muscular atrophy (SMA)
with primary involvement of proximal muscles and progressive
cerebellar atrophy was detailed in patients with the T424R
mutation19,22, while diagnosis of patients with the S87L mutation
was CMT with SMA-like features16,21. We recently showed that
the CMT-associated MORC2 mutation R252W hyperactivates
HUSH-mediated epigenetic silencing in neuronal cells4. Disease
mutations in MORC2 map to the ATPase module, as in the
related SMCHD1 protein, where mutations have recently been
associated with Bosma arhinia microphthalmia syndrome
(BAMS)24,25. However, the lack of biochemical or structural data
on MORC2 has precluded the efforts to understand its molecular
function and rationalize the phenotypes of this rapidly growing
list of neuropathic MORC2 variants.
Here we report the biochemical and cellular activities of
MORC2 variants, alongside structures of wild-type and neuro-
pathic variant forms of a MORC2 fragment comprising the
GHKL-type ATPase module and CW domain. Our data reveal
several functionally critical features of MORC2. We show how the
ATPase activity of MORC2 is tuned, and how ATP-dependent
dimerization and DNA binding transduce HUSH-dependent
silencing. We propose distinct structural mechanisms that explain
how these functions of MORC2 are misregulated in neuropathy-
associated variants: destabilization of the ATPase-CW module,
trapping the ATP lid, or perturbing the dimer interface. Together,
our data provide a molecular understanding of the multiple
structural mechanisms underlying the neuropathic effects of
MORC2 mutations.
Results
Isolation of an active GHKL ATPase module of MORC2. We
set out to purify human MORC2 constructs suitable for bio-
chemical and structural studies. MORC2 is a 1032-amino acid
protein predicted to contain several functional domains including
an N-terminal GHKL-type ATPase module with a coiled-coil
insertion (CC1) (Fig. 1a). MORC3 lacks the CC1 insertion, and its
ATPase module can be produced in E. coli11,15, but we were
unable to purify soluble human MORC2 with an intact CC1 from
bacteria. We puriﬁed MORC2(1–282) (i.e., the GHKL domain,
but not including CC1 or the remainder of the ATPase module)
and used native differential scanning ﬂuorimetry (DSF) to
monitor its interaction with non-hydrolysable ATP analog
AMPPNP. Native DSF exploits the intrinsic ﬂuorescence prop-
erties of proteins to monitor thermal unfolding processes, which
are usually accompanied by a redshift in the ﬂuorescence max-
imum wavelength from 330 nm to 350 nm. By monitoring the
ratio of ﬂuorescence at these wavelengths as a function of tem-
perature, a melting temperature (Tm) may be extracted in the
absence and presence of stabilizing ligands. We found that
although we could detect a small thermal stabilization of MORC2
(1–282) by Mg2+/AMPPNP, indicating an interaction, no ATPase
activity was detected using this construct in an endpoint assay
based on the detection of inorganic phosphate (Fig. 1b and
Supplementary Fig. 1a). We could express and purify full-length
MORC2 bearing a cleavable tandem StrepII tag in insect cells
using a baculovirus-based expression system, but obtained low
yields, and the protein was highly sensitive to proteolytic cleavage.
We used limited proteolysis to identify a protease-resistant N-
terminal fragment that ran at ~75 kDa by SDS-PAGE and showed
evidence of ATP hydrolysis activity (Supplementary Fig. 1a,b).
Based on the sequencing of tryptic peptides by tandem mass
spectrometry, we designed a construct spanning residues 1–603,
encompassing the N-terminal ATPase module, the CW domain,
and the second predicted coiled coil (CC2).
MORC2(1–603) from insect cells was stabilized by Mg2+/
AMPPNP, leading to a large increase in the protein Tm from 51.5
to 67.3 °C as measured by DSF (Fig. 1b and Supplementary
Fig. 1c). By contrast, concentrations up to 2 mM of Mg2+/ADP
and inorganic phosphate (the products of ATP hydrolysis) did
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not stabilize the protein (Supplementary Fig. 1c). We then
performed size-exclusion chromatography (SEC) coupled to both
multi-angle light scattering (MALS) and quasi-elastic light
scattering (QELS) to assess the oligomerization status. MALS
analysis was consistent with the apo protein being monomeric,
and dimerizing in the presence of 2 mM AMPPNP (Fig. 1c).
QELS data showed that nucleotide-dependent dimerization was
accompanied by an increase in the hydrodynamic radius (Rh)
from 3.3 nm to 4.4 nm (Fig. 1c).
MORC2 was previously reported to have ATPase activity in an
assay using cellular extracts and in which the D68A point mutant
was used as a negative control9. We were unable to purify
MORC2 constructs bearing the D68A mutation from either
bacterial or eukaryotic cells, suggesting that it may cause
misfolding of the ATPase module. Since GHKL-type ATPases
are usually inefﬁcient enzymes, a robust negative control is
essential to rule out background activity from more efﬁcient,
contaminating ATPases. Hence, we performed an ATPase assay
with puriﬁed components, using the classical NADH-coupled
system that has been used for DNA gyrase and Hsp90 in order to
measure enzyme kinetics in continuous mode26,27. For the
negative control, we mutated the highly conserved active site
residue Asn39; the N39A mutation did not compromise the
folding of MORC2, but abrogated binding of Mg2+/AMPPNP
according to DSF data and SEC (Fig. 1b and Supplementary
Figs. 2 and 8). Puriﬁed wild-type MORC2(1–603) was found to
have weak but measurable ATPase activity, while the N39A
mutant was inactive (Fig. 1d). The kinetics we measured were
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Fig. 1 MORC2 is a GHKL-type ATPase. a Domain organization of human MORC2. The GHKL ATP binding domain and the transducer-like domain (trans.)
together form the ATPase module, as marked. CC indicates a predicted coiled coil; CW indicates a CW-type zinc ﬁnger domain; TCD indicates a predicted
tudor-chromodomain. b Fitted Tm s derived from differential scanning ﬂuorimetry (DSF) for several MORC2 variants at 5 µM, in the absence (solid bar) and
presence (striped bar) of 2 mM Mg-AMPPNP. This non-hydrolysable ATP analog signiﬁcantly increases the thermal stability of wild-type (WT) MORC2
(1–603), while the N39A point mutant abrogates binding and WT MORC2(1–282) is stabilized to a much smaller extent than WT MORC2(1–603). Quoted
Tm values are an average of at least two replicates; note that the deviation between these measurements was <0.2 °C in all cases. c Portions of overlaid
SEC-MALS UV traces for 40 µMWTMORC2(1–603) in the absence (solid line) and presence (dashed line) of 2 mMMg-AMPPNP. The MALS data across
the center of the major peaks in each case are shown on the right-hand axis, and are consistent with monomeric (expected mass: 70 kDa) and dimeric
(expected mass: 140 kDa) species for the apo and AMPPNP-bound protein, respectively. Also shown are the ﬁtted hydrodynamic radii obtained from QELS
analysis of the peaks. The peak at 48min in the AMPPNP-treated trace is the elution of excess (unbound) nucleotide. d Rate of ATP hydrolysis by wild-
type (WT) and N39A MORC2(1–603) variants at 37 °C in the presence of 7.5 mM ATP, measured using an NADH-coupled continuous assay. Error bars
represent standard deviation between measurements; n= 8 (WT), n= 7 (N39A). e Steady-state ATPase activity of 4 µM WT MORC2(1–603) at 37 °C
ﬁtted to a model of Michaelis–Menten kinetics
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typical of GHKL ATPases, with a ﬁtted kcat of 0.10 min-1 and Km
(ATP) of 378± 53 µM (Fig. 1e). Together, these data indicate that
the wild-type MORC2 N-terminal ATPase module dimerizes
upon ATP binding and that dimers dissociate upon ATP
hydrolysis.
Structure of the homodimeric N terminus of human MORC2.
Having isolated a MORC2 construct competent for nucleotide
binding and hydrolysis, we sought to generate mechanistic
insights into the biochemical properties of MORC2 and the
molecular basis of MORC2-associated neuropathies via structural
analysis. We obtained crystals of human MORC2(1–603) in the
presence of a molar excess of AMPPNP. The structure was
determined by molecular replacement, using the murine MORC3
ATPase module structure11 as a search model. The asymmetric
unit contained two MORC2 molecules and the structure was
reﬁned to 1.8 Å resolution (Table 1).
The overall architecture of the crystallized MORC2 fragment
bound to AMPPNP is an almost symmetric, parallel homodimer
resembling the letter M (Fig. 2a). Using the program HYDRO-
PRO28, we calculated the radius of gyration (Rg) of our model to
be 3.4 nm. This value is in good agreement with the hydro-
dynamic radius (Rh), 4.4 nm, obtained from QELS analysis of the
AMPPNP-bound dimer in solution; theory states that for globular
proteins, Rg/Rh ~0.7729. A 2778 Å2 surface from
each monomer is buried at the dimer interface. Structural
alignment of the ATPase modules of MORC2 and MORC3 gave
an rmsd of 1.29 Å for 2200 backbone atoms, with 36% sequence
identity.
The MORC2 ATPase module consists of two α-β-α sandwich
domains, that we have distinguished as the GHKL domain
(residues 1–265) and the transducer-like domain (residues
266–494, previously annotated as the S5 domain) due to its
resemblance to the transducer domain of gyrase30,31. Notably, the
β-sheet in the transducer-like domain contains an 80-amino acid
antiparallel coiled-coil insertion, CC1 (residues 282–361), which
forms a 6-nm projection emerging from the ATPase module. A
similar insertion is predicted in MORC1, but is absent in other
GHKL superfamily members. The transducer-like domain is
capped by a helix-loop-helix motif that links to the CW domain
(residues 495–545). This motif is disordered in the
MORC3 structure and, moreover, the CW domain of MORC2
is in a completely different position and orientation relative to the
ATPase module. Our MORC2 structures span residues 1–551,
including all reported sites of neuropathy-causing mutations
(Supplementary Fig. 3a,b). We did not observe electron density
for the second predicted coiled coil, CC2 (residues 551–603).
A tetrahedrally coordinated zinc atom carried over from
the puriﬁcation was observed bound to the CW domain.
The presence of zinc in the MORC2 crystals was conﬁrmed
by X-ray ﬂuorescence spectroscopy (Supplementary Fig. 3c).
MORC2 has a prototypical GHKL ATPase active site. One
AMPPNP molecule, stabilized by an octahedrally coordinated
Mg2+ ion, is bound in the active site of both protomers. All
critical residues involved in ATP binding and hydrolysis from the
four signature motifs in the N-terminal GHKL ATP-binding
domain32 are conserved (Supplementary Fig. 3d,e): from Motif I
(helix α2 in MORC2), Glu35 acts as a general base for water
activation and Asn39 coordinates the Mg2+ ion that templates the
water-mediated interactions of the α-, β-, and γ- phosphates;
from Motif II, Asp68 hydrogen bonds to the adenine-N6-amine
and the bulky sidechain of Met73 stacks against the adenine ring,
while Gly70 and Gly72 (the ‘G1 box’) appear to provide ﬂexibility
to the ensuing ‘ATP lid’; from Motif III, Gly98, Gly101, and
Gly103 form the ‘G2 box’ at the other end of the lid and Lys105
forms a salt bridge with the α-phosphate; and from Motif IV,
Thr119 and Thr197 contribute to the stabilization of Motif II and
the adenine ring, respectively. Lys427 from the transducer-like
domain coordinates the γ-phosphate of AMPPNP, and forms a
hydrogen bond with the same activated water nucleophile bound
by Glu35. As in other GHKL family members, this conserved
lysine from the transducer-like domain completes the functional
ATPase.
Nucleotide binding of MORC2 stabilizes dimer interface.
GHKL ATPases usually dimerize on binding ATP, but the
composition and dynamics of the ATP lid that can close over the
active site vary across the GHKL superfamily32. In the wild-type
MORC2 structure, the ATP lid (residues 82–103) is in the closed
conformation in both protomers, leaving only a narrow channel
between the bound AMPPNP and the solvent. Aside from resi-
dues in the four motifs detailed above, protein–nucleotide inter-
actions made by the sidechains of Ser87 (notably, a neuropathy
mutation site) and Lys89 with the β-phosphate, and by the
backbone atoms of Gln99 and Tyr100 with the γ-phosphate,
stabilize the lid conformation (Fig. 2b). Residues in the lid form a
Table 1 X-ray data collection and reﬁnement statistics for
crystal structures of MORC2(1–603) variants reported in
this paper
WT T424R S87L
Ligand AMP-PNP AMP-PNP ATP
Data collection
X-ray source ESRF ID30b ESRF ID29 ESRF ID29
Space group P1211 P1211 P1211
Cell dimensions
a, b, c (Å) 66.17, 127.93,
80.19
69.61, 125.73,
81.53
69.85, 124.68,
80.36
α, β, γ (°) 90.0, 101.2,
90.0
90.0, 97.8,
90.0
90.0, 97.7,
90.0
Wavelength (Å) 0.972636 0.975999 0.975999
Resolution (Å)a 78.66–1.81
(1.84–1.81)
80.76–2.57
(2.62–2.57)
79.63–2.02
(2.05–2.02)
Observations 789,315 165,185 309,681
Unique reﬂections 118,148 43,876 82,175
Rmerge 0.082 (0.901)
a
0.046 (0.599)a 0.052 (0.648)a
<I>/σ(I)a 13.6 (2.1) 16.2 (2.1) 13.5 (2.2)
Completeness (%)a 98.9 (98.3) 99.6 (99.4) 91.9 (96.7)
Redundancya 6.9 (6.3) 3.8 (3.7) 3.8 (3.7)
Reﬁnement
Rwork/Rfree 0.161/0.188 0.211/0.239 0.198/0.228
No. of non-H atoms
Protein 8708 8696 8713
Ligand/ions 66 66 67
Solvent 721 39 304
Mean B-factors
Protein 44.0 93.1 53.8
Ligand/ions 24.1 52.0 34.9
Solvent 45.4 57.2 47.0
RMSD
Bond lengths (Å) 0.012 0.014 0.015
Bond angles (°) 1.108 1.935 1.930
Ramachandran stats
% Favored 97.36 97.07 97.27
% Allowed 2.45 2.84 2.54
% Outliers 0.19 0.09 0.19
PDB code 5OF9 5OFA 5OFB
aValues in parentheses refer to the highest-resolution shell.
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signiﬁcant part of the dimer interface, with Ile82, Phe84, Arg90,
Tyr100, and Asn102-forming hydrogen bonds and hydrophobic
contacts with residues 12–24 of the other protomer. A loop in the
transducer-like domain (residues 422–437) also contributes to the
dimer interface. This loop coordinates the γ-phosphate of
AMPPNP through Lys427 (and includes another neuropathy
mutation site, Thr424) (Fig. 2c). Residues 1–11 form the
remaining contacts of the dimer interface, extending across all
three layers of the GHKL domain of the other protomer.
The majority of the dimer contacts are formed by loops that
directly coordinate ATP and are likely to have a different, more
ﬂexible structure in the absence of ATP. This demonstrates how
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ATP binding and dimerization of MORC2 are coupled
structurally.
Dimerization of MORC2 is required for HUSH silencing. The
MORC2(1–603) N39A mutant is monomeric in solution and
does not bind or hydrolyze ATP (Fig. 1b,d and Supplementary
Fig. 1c, 2). Since ATP binding by the MORC2 ATPase module is
coupled to dimerization, we conclude that the catalytically inac-
tive N39A mutant does not form dimers via the ATPase module.
We previously established a genetic complementation assay to
assess the capacity of different disease-associated variants of
MORC2 to rescue HUSH-dependent transgene silencing in
MORC2 knockout (KO) cells. Brieﬂy, we isolated clonal HeLa
reporter cell lines bearing a HUSH-repressed GFP reporter.
CRISPR-mediated KO of MORC2 in these clones led to the cells
becoming GFP bright, allowing complementation with exogenous
MORC2 variants, which can be monitored as GFP re-repression
using FACS4. The lentiviral vector used expresses mCherry from
an internal ribosome entry site (IRES), enabling us to control for
multiplicity of infection (MOI) by monitoring mCherry. Using
this assay, we previously found that the N39A mutant failed to
rescue HUSH-dependent silencing4. Together with our bio-
chemical data, this shows that ATP binding or dimerization of
MORC2 (or both) is required for HUSH function.
To decouple the functional roles of ATP binding and
dimerization, we used our MORC2 structure to design a mutation
aimed at weakening the dimer interface without interfering with
the ATP-binding site. The sidechain of Tyr18 makes extensive
dimer contacts at the two-fold symmetry axis, but is not located
in the ATP-binding pocket (Fig. 2c). Using the genetic
complementation assay described above, we found that although
the addition of exogenous V5-tagged wild-type MORC2 rescued
HUSH silencing in MORC2-KO cells, the Y18A MORC2 variant
failed to do so (Fig. 2d). Interestingly, the inactive MORC2 Y18A
variant was expressed at a higher level than wild type despite the
same MOI being used (Fig. 2e).
We then puriﬁed MORC2(1–603) Y18A and analyzed its
stability and biochemical activities. Consistent with our design,
the mutant was monomeric even in the presence of 2 mM
AMPPNP according to SEC-MALS data (Fig. 2f). Despite its
inability to form dimers, MORC2(1–603) Y18A was able to bind
and hydrolyze ATP, with slightly elevated activity over the wild-
type construct (Fig. 2g). This demonstrates that dimerization of
the MORC2 N terminus is not required for ATP hydrolysis.
Taken together, we conclude that ATP-dependent dimerization of
the MORC2 ATPase module transduces HUSH silencing, and
that ATP binding and hydrolysis are not sufﬁcient.
CC1 domain of MORC2 has rotational ﬂexibility. A striking
feature of the MORC2 structure is the projection made by CC1
(residues 282–361) that emerges from the core ATPase module.
The only other GHKL ATPase with a similar coiled-coil insertion
predicted from its amino acid sequence is MORC1, for which no
structure is available. Elevated B-factors in CC1 suggest local
ﬂexibility and the projections emerge at different angles in each
protomer in the structure. The orientation of CC1 relative to the
ATPase module also varies from crystal-to-crystal, leading to a
variation of up to 19 Å in the position of the distal end of CC1
(Fig. 3a). Although the orientation of CC1 may be inﬂuenced by
crystal contacts, a detailed examination of the structural variation
reveals a cluster of hydrophobic residues (Phe284, Leu366,
Phe368, Val416, Pro417, Leu419, Val420, Leu421, and Leu439)
that may function as a ‘greasy hinge’ to enable rotational motion
of CC1. Notably, this cluster is proximal to the dimer interface.
Furthermore, Arg283 and Arg287, which ﬂank the hydrophobic
cluster at the base of CC1, form salt bridges across the dimer
interface with Asp208 from the other protomer, and further along
CC1, Lys356 interacts with Glu93 in the ATP lid (Fig. 3b). Based
on these observations, we hypothesize that dimerization, and
therefore ATP binding, may be coupled to the rotation of CC1,
with the hydrophobic cluster at its base serving as a hinge.
Distal end of CC1 contributes to MORC2 DNA-binding
activity. CC1 has a predominantly basic electrostatic surface, with
24 positively charged residues distributed across the surface of the
coiled coil (Fig. 3c). MORC3 was shown to bind double-stranded
DNA (dsDNA) through its ATPase module, but this interaction
was autoinhibited by the CW domain15. Therefore, we sought to
determine whether the MORC2 ATPase-CW cassette binds DNA,
and whether the charged surface of CC1 contributes to DNA
binding. We ﬁrst performed electrophoretic mobility shift assays
with nucleosome core particles (NCPs) and observed that wild-
type MORC2(1–603) bound to both free DNA and nucleosomal
DNA present in the NCP sample, with an apparent preference for
free DNA (Fig. 3d).
Next, to assess the importance of CC1 in HUSH-dependent
silencing, we examined the effect of a panel of charge reversal
mutations in CC1 in the cell-based HUSH complementation
assay. The charge reversal point mutations R319E, R344E, R351E,
and R358E all rescued HUSH function in MORC2-KO cells, but
R326E, R329E, and R333E (or combinations thereof) failed to do
so (Fig. 3e and Supplementary Fig. 4a). Again, inactive variants
were expressed at higher levels than active ones (Supplementary
Fig. 4b). Residues 326, 329, and 333 form a positively charged
patch near the distal end of the second α-helix of CC1. We
therefore made a MORC2(1–603) triple mutant, R326E/R329E/
R333E, and compared its dsDNA binding to that of the WT
construct. We conﬁrmed that WT MORC2(1–603) bound to the
canonical Widom 601 nucleosome positioning sequence with
high apparent afﬁnity, and observed a ‘laddering’ effect on the
Fig. 2 ATP binding and dimerization of MORC2 are tightly coupled and required for HUSH-dependent transgene silencing. a Crystal structure of
homodimeric human MORC2 residues 1–603 in complex with Mg-AMPPNP reﬁned at 1.8 Å resolution. One protomer is colored according to the domain
structure scheme (top), and the other is colored in orange. The protein is shown in cartoon representation, nucleotides are shown in stick representation,
and metal ions are shown as spheres. Solvent molecules are not shown. b, c Nucleotide binding and dimerization are structurally coupled. Residues in the
ATP lid (pink, residues 82–103), which covers the active site (b) and in a loop from the transducer-like domain (c) contribute to the interactions at
the dimer interface. Key sidechains are shown in stick representation; labeled residues from the second protomer are marked with an asterisk. d, e
Dimerization is critical for mediating HUSH-dependent transgene silencing activity. Expression of a MORC2 variant bearing an alanine substitution at a key
residue in the dimer interface (Y18A) failed to rescue repression of a GFP reporter in MORC2 knockout cells, as assessed by FACS. Shown are the data
from Day 12 post-transduction: the GFP reporter ﬂuorescence of the HUSH-repressed clone is in gray; the MORC2 knockout is in green; the MORC2
knockout transduced with exogenous MORC2 variants is in orange (d). The lentiviral vector used expresses mCherry from an internal ribosome entry site
(IRES), enabling control of viral titer by mCherry ﬂuorescence measurement. Despite using the same MOI, the Y18A variant was expressed at higher levels
than wild-type (WT) as assessed by a Western blot of cell lysates (e). f, g Y18A MORC2(1–603) does not undergo ATP-dependent dimerization, but is
able to bind and hydrolyze ATP, based on SEC-MALS data in the presence of 2 mMMg-AMPPNP (f) and ATPase assays (g). Error bars represent standard
deviation between measurements; n= 8. The data for WT (blue) from Fig. 1c, d are shown for reference
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EMSA with 500 nM nucleosome core particles (NCPs) in the presence of increasing concentrations of MORC2(1–603). Negative controls were performed
with SDS-containing loading dye, which denatures proteins, and with a protein of similar size (−ve, concentrations at 0.5 and 2.5 µM). The positive control
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disappearance of unbound DNA band with protein titration. Gels were post-stained for DNA with 2 µM SYTO62
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03045-x ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:651 |DOI: 10.1038/s41467-018-03045-x |www.nature.com/naturecommunications 7
DNA at the lowest (250–750 nM) protein concentrations. This is
consistent with multiple DNA-binding surfaces on the protein,
DNA modiﬁcation and/or multiple proteins binding to a single
piece of DNA. The triple CC1 charge reversal mutant still bound
dsDNA, but with weaker apparent afﬁnity, and no laddering of
the DNA bands was observed (Fig. 3f). We conﬁrmed that this
mutant was folded and was able to bind and hydrolyze ATP
(Supplementary Fig. 4c). The WT MORC2 GHKL domain alone
(residues 1–282) also bound dsDNA, albeit with a much lower
afﬁnity and with no laddering, whereas the CW domain in
isolation did not bind DNA in the EMSA (Supplementary Fig. 4d,
e). Together, these data suggest that MORC2 binds dsDNA
through multiple sites including a positively charged surface near
the distal end of the CC1 arm, and that the latter is required for
transduction of HUSH-dependent silencing.
CW domain of MORC2 regulates its HUSH effector function.
Several recent studies have shown that the CW domain of
MORC3 binds H3K4me3 peptides selectively over histone 3
peptides with other epigenetic marks11,14,15. By contrast, the
MORC2 CW domain does not bind to the H3K4me3 mark due to
a missing tryptophan at the ‘ﬂoor’ of the CW aromatic cage
(Thr496 in MORC2, Fig. 4a)4,14. Indeed, the MORC2 CW
domain was found not to interact with any of the wide variety of
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histone H3 and histone H4 peptides14. We conﬁrmed that the
lack of interaction with DNA and/or histones is not due to a
folding defect or a reliance on the ATPase module for folding,
since isolated 15N-labeled MORC2 CW domain gave well-
dispersed peaks in a 1H, 15N-heteronuclear single quantum
coherence experiment (Supplementary Fig. 5a).
The orientation of the CW domain relative to the ATPase
module differs by approximately 180˚ in the MORC2 and
MORC3 structures, with the degenerate histone-binding site of
the MORC2 CW domain facing toward the ATPase module
rather than toward solvent (Supplementary Fig. 5b). The CW
domain binds an array of arginine residues in the transducer-like
domain: conserved residue Trp505, providing the ‘right wall’ of
the methyl-lysine-coordinating aromatic cage, forms a cation–π
interaction with the sidechain of Arg266. Thr496 (the degener-
ated ‘ﬂoor’ residue) makes a water-mediated hydrogen bond with
the backbone amide of Arg266. Asp500 forms a salt bridge with
Arg254. Gln498 forms a hydrogen bond with the backbone
carbonyl oxygen of Arg252. Glu540 forms a salt bridge with the
Arg252 sidechain, which also forms a hydrogen bond with the
backbone oxygen atom of Leu503 (Fig. 4b). The latter interactions
are notable since a number of recent studies have shown that the
R252W mutation causes CMT disease16,17,20,21. We recently
demonstrated that this mutation causes hyperactivation of
HUSH-dependent epigenetic silencing4, leading to enhanced
and accelerated re-repression of the GFP reporter in our
functional assay. The R252W mutation, by removing the salt
bridge to Glu540, may destabilize the ATPase–CW interface,
which could account for the misregulation of MORC2 function in
HUSH-dependent silencing. To test this hypothesis, we designed
a mutation aimed at causing a similar structural defect, R266A,
which disrupts the cation–π interaction with Trp505 described
above. We performed a timecourse experiment, monitoring GFP
reporter ﬂuorescence in MORC2-KO cells after addition of the
exogenous MORC2 variant. The R266A mutation recapitulated
the hyper-repressive phenotype of R252W in the reporter clone
tested (Fig. 4c, d). In contrast to inactive variants, these
hyperactive variants were expressed at lower levels than wild
type (Fig. 4e). These data support the notion that the
ATPase–CW interaction in MORC2 has a regulatory function
in HUSH transgene silencing.
In MORC3, the CW domain prevents binding of the ATPase
module to DNA in the absence of the H3K4me3 peptide15. In
MORC2, however, the CW domain does not inhibit DNA
binding since MORC2(1–603) bound tightly to DNA despite the
presence of an unliganded CW domain (Fig. 3d, f). We note that
many of the sidechains forming key contacts in the ATPase–CW
domain interfaces of MORC2 and MORC3 are not conserved in
the two proteins. These non-conserved residues are Arg254,
Arg266, and Thr496 in MORC2 and Glu184, Arg195, Lys216,
Tyr217, Arg405, Arg444, and Asp454 in MORC3. Hence, it
appears unlikely that the CW domain can bind to the MORC2
ATPase module in the same conﬁguration as in MORC3, and vice
versa. Together, our data show that the CW domain of MORC2
has a degenerate aromatic cage that explains its lack of binding to
epigenetic marks on histone tails, and suggest that the association
of the CW domain to the ATPase module antagonizes HUSH-
dependent epigenetic silencing. Moreover, we conclude that
MORC2 and MORC3 have evolved CW domains with distinct
regulatory mechanisms.
Disease mutations modulate the activities of MORC2. We next
tested whether MORC2 mutations reported to cause neuropathies
affected the ATPase activity of MORC2. We puriﬁed MORC2
(1–603) variants containing the R252W, T424R, and S87L point
mutations. All of the variants were folded and were thermally
stabilized by addition of 2 mM Mg2+/AMPPNP (Supplementary
Figs. 2, 6a). We found a range of effects on ATPase activity
(Fig. 5a). MORC2(1–603) bearing CMT mutation
R252W16,17,20,21 showed a small decrease in the rate of ATP
hydrolysis. In contrast, SMA mutation T424R19,22 increased
ATPase activity by approximately three-fold. The S87L variant
(for which the clinical diagnosis was CMT with SMA-like fea-
tures16,21) eluted from a size-exclusion column as two species: a
major species that eluted earlier than other variants and displayed
elevated 260 nm absorbance (Supplementary Fig. 2), suggestive of
dimerization and the presence of bound nucleotide(s), and a
minor, presumably monomeric, species. This variant displayed
low ATPase activity, near the detection threshold.
The R252W MORC2 variant hyperactivates HUSH-mediated
transgene silencing4, but has reduced ATPase activity in vitro. We
used the timecourse HUSH functional assay in two distinct
MORC2-KO GFP reporter clones (i.e., two different HUSH-
repressed loci) to investigate further the correlation of these
activities (Fig. 5b). S87L (which has reduced ATPase activity
in vitro) also matched or outperformed wild-type MORC2 at each
time point measured. Conversely, T424R (which has increased
ATPase activity in vitro) was signiﬁcantly less efﬁcient at GFP
reporter repression than wild-type at both loci (Fig. 5b and
Supplementary Fig. 6b,c). Using SEC-MALS to investigate the
oligomerization of S87L and T424R mutants, we conﬁrmed that
S87L forms constitutive N-terminal dimers with no exogenous
addition of nucleotide, while T424R forms a mixture of
monomers and dimers in the presence of 2 mM AMPPNP
(Fig. 5c). Together, these data indicate that unlike the point
mutants incompetent for ATP binding (N39A) or dimerization
(Y18A), which altogether fail to transduce HUSH silencing, the
disease-associated variants are all capable of ATP binding,
dimerization, and hydrolysis. Further, we ﬁnd that the efﬁciency
of HUSH-dependent epigenetic silencing decreases as the rate of
ATP hydrolysis increases. A summary of the properties of
neuropathic and engineered MORC2 variants is shown in
Table 2.
Neuropathic mutations perturb MORC2 dimer interface. Two
MORC2 mutations, S87L and T424R, have been reported to cause
congenital or infantile onset of neuropathies, distinct from the
later onset that was reported for patients bearing the R252W (or
other) mutations. The consequences of S87L and T424R muta-
tions on the biochemical activities of MORC2 are drastic. The
locations of these mutation sites—Ser87 in the ATP lid and
Thr424 at the dimer interface—are also at functionally important
regions in the structure and we determined the crystal structures
of these variants to understand better the observed activities
(Table 1). T424R MORC2 was co-crystallized with AMPPNP
using the same protocol as for wild-type MORC2, but since S87L
was dimeric and nucleotide-bound upon puriﬁcation from insect
cells, we determined its structure bound to ATP. The overall
homodimeric structure of the two MORC2 disease variants was
very similar to that of the wild type (Supplementary Fig. 7). The
orientation of CC1 relative to the ATPase module varied in each
protomer within the same range as in wild type. The ATP
molecules bound to S87L MORC2 were found in a nearly iden-
tical conformation to AMPPNP in the wild-type and T424R
structures, conﬁrming that AMPPNP is a reasonable mimic of the
natural nucleotide substrate in this case.
Ser87 is in the lid that covers bound ATP. Its sidechain
hydroxyl forms a hydrogen bond with the β-phosphate of
AMPPNP in the wild-type structure. In the S87L mutant, we
found that the lid is partially missing in one protomer and has a
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completely different conformation in the other. In the latter
protomer, the lid forms additional contacts across the dimer
interface in the S87L mutant (Fig. 5d). Leu87 itself forms apolar
contacts with Asp141 from the other protomer, but more
importantly, Arg90 forms a tight salt bridge with Glu17 across
protomers. In the wild-type structure the Arg90 and
Glu17 sidechains are 4–5 Å apart, but do not form a salt bridge.
Instead, Lys86 can form a salt bridge with Asp141 from the other
protomer in wild-type. The increased number of dimer contacts
in the S87L mutant is reﬂected in an increased buried surface area
at the dimer interface (3016 Å2 buried per protomer versus 2778
Å2 in wild-type). These observations provide a plausible
structural basis for the observation that S87L forms more stable
ATP-bound dimers than wild-type, which in turn affects its
cellular function.
The effect of T424R on the crystal structure of MORC2 is more
subtle. The backbone structures of wild-type and T424R are
essentially identical, including in the loop that contains the
mutation (Fig. 5e). The arginine sidechain in the mutant does
make an additional salt bridge across the dimer interface, with
Glu27 from the other protomer. This additional contact may
contribute to the dimer interface, but we did not observe any
dimerization of T424R MORC2 during puriﬁcation, suggesting
that the mechanism of misregulating MORC2 is distinct from
S87L. Moreover, the buried surface area at the dimer interface is
actually decreased upon the T424R mutation (2527 Å2 buried per
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protomer versus 2778 Å2 in wild type). We have described how
ATP binding/hydrolysis is structurally coupled to dimerization/
dissociation. The contribution of the mutant Arg424 sidechain to
the dimer interface, and its position just three residues away from
a key active site residue Lys427, can be expected to alter the ATP-
dependent dimerization dynamics of MORC2. Indeed, we found
that the T424R variant forms a mixture of monomers and dimers
in the presence of AMPPNP, and shows an elevated rate of ATP
hydrolysis. This suggests that T424R dimers may form and
dissociate more rapidly than in the wild type. It should be noted,
however, that MORC2-associated neuropathies are subject to
autosomal dominant inheritance. Therefore, our structures
represent the physiologically less common species in which not
one but both protomers bear the mutation. It may be that the
effect on molecular function is subtly different in heterozygous
MORC2 dimers. Together, these data show that S87L causes
kinetic stabilization of MORC2 dimers, whereas T424R increases
the rate of dimer assembly and disassembly (summarized in
Fig. 5f). These two disease mechanisms are distinct from that of
R252W, which we propose above to weaken the regulatory
ATPase–CW interaction.
Discussion
Genetic studies have established that MORC family proteins have
fundamentally important functions in epigenetic silencing across
eukaryotic species1,4,5,8. We recently identiﬁed MORC2 as an
effector of the HUSH complex and showed that MORC2 con-
tributes to chromatin compaction across HUSH target loci. The
activity of MORC2 was dependent on ATP binding by its GHKL-
type ATPase module4. Here, our structural and biochemical
analyses provide evidence for how ATP binding and dimerization
of MORC2 are coupled to each other.
To understand how the biochemical activity of MORC2 is
related to its cellular function, a comparison to prototypical
GHKL ATPases is informative. The Km for ATP and kcat of the
MORC2 N-terminal fragment, 0.37 mM and 0.1 min-1, respec-
tively, are of comparable magnitude to those measured for
recombinant constructs of E. coli DNA gyrase B (GyrB) (0.45 mM
and 0.1 min-1)33, human Hsp90 (0.84 mM and 0.007 min-1)34,
and MutL (0.09 mM and 0.4 min-1)35. The Km of MORC3 has not
been reported, but its activity at 3 mM ATP was 0.4–0.5 min-1.15
Hence, MORC2 and MORC3 resemble prototypical GHKL
ATPases in that they bind ATP with relatively low afﬁnity and
hydrolyze ATP relatively slowly. Due to their low enzymatic
turnover, GHKL ATPases are not known to function as motors or
deliver a power stroke. Instead, ATP binding and hydrolysis
function as conformational switches triggering dimer formation
and dissociation, respectively36. Since MORC2 has similar
enzymatic properties to other GHKL ATPases, we propose that
its HUSH effector function arises from dimerization of its ATPase
module triggered by ATP binding. Consistent with this model, a
mutation outside the active site that inhibits dimerization of the
ATPase module without affecting ATP binding/hydrolysis
(Y18A) causes a loss of HUSH silencing (Fig. 2d–g). Since ATP
hydrolysis leads to dissociation of the dimer, one corollary is that
increasing the rate of hydrolysis should cause less efﬁcient HUSH
function, and decreasing the rate of hydrolysis should hyper-
activate HUSH function (so long as the protein can undergo
ATP-dependent dimerization). Indeed, this is what we found
through analysis of the three neuropathy-associated MORC2
mutants: T424R, which hydrolyzes ATP more rapidly than wild-
type, leads to less efﬁcient HUSH silencing, whereas S87L and
R252W, which hydrolyze ATP more slowly than wild-type, match
or hyperactivate wild-type HUSH silencing (Fig. 5). We conclude
that the lifetime of wild-type MORC2 ATPase dimers is tuned to
enable cellular function. Indeed, the properties of engineered and
naturally occurring MORC2 variants studied so far (summarized
in Table 2) suggest that slight changes in the rate of ATP
hydrolysis or dimer stability misregulate MORC2 cellular func-
tion by perturbing its N-terminal dimerization dynamics.
Our data suggest that the biological function of MORC2 arises
from cycling between monomeric and dimeric conformational
states at a ﬁnely tuned rate deﬁned by ATP binding and hydro-
lysis—but what is the effect of MORC2 dimerization in the cell?
The MORC2 N-terminal fragment binds dsDNA with high afﬁ-
nity as a monomer. Dimerization of two DNA-bound MORC2
molecules would bring two DNA duplexes together, which could
promote DNA loop formation and chromatin compaction.
MORC3 and SMCHD1 also bind DNA and have both been
proposed to function as molecular clamps on DNA11,37,38. If
MORC2 acts as a DNA clamp, the lifetimes of open and closed
forms will be determined by the dimerization dynamics of the
ATPase module. Structural and biochemical studies on full-length
MORC2 are necessary to investigate whether MORC2 functions
as a clamp and to better understand how it interacts with
chromatin.
The structure of MORC2 contains a coiled-coil insertion in the
ATPase module, CC1, which forms a positively charged 6-nm
projection. A similar insertion is predicted in MORC1 (and in
certain MORCs from other species including MORC1 from C.
elegans, the sole annotated MORC in that species3), but not in
other GHKL ATPases. MORC2 CC1 contributes to DNA bind-
ing, and charge reversal mutations at the distal end of CC1 cause
a change in DNA-binding properties and loss of HUSH function.
Comparison of MORC2 structures from different crystals shows
that a cluster of hydrophobic residues, where CC1 emerges from
Fig. 5 Neuropathy-associated mutations modulate the ATPase and HUSH-dependent silencing activities of MORC2 by perturbing its N-terminal
dimerization dynamics. a Rate of ATP hydrolysis by wild-type (WT) and neuropathic variants of MORC2(1–603) at 37 °C and 7.5 mM ATP, measured
using an NADH-coupled continuous assay. Error bars represent standard deviation between measurements; n= 8 (WT), n= 10 (R252W), n= 5 (T424R
and S87L). The WT data are shown for reference and are the same as in Fig. 1d. b Assessing the efﬁciency of HUSH-mediated silencing by neuropathic
MORC2 variants. Time-course of transgene re-repression by MORC2 variants in two distinct MORC2-knockout GFP reporter clones (i.e., two different
HUSH-repressed loci). The bar chart shows the relative GFP ﬂuorescence (FACS-derived geometric mean) of complemented cells compared to untreated
cells (*P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001, ns: not signiﬁcant, unpaired t-test compared to wild-type data). Error bars represent the mean±
standard deviation from three biological replicates. nd, not determined. See also Supplementary Figs. 6b,c. c Portions of overlaid SEC-MALS UV traces for
neuropathic variants of MORC2(1–603). Left, 7.5 µM S87L MORC2(1–603) (light blue) as puriﬁed from insect cells with no additional nucleotide (WT apo
data shown for comparison). Right, 7.5 µM T424R MORC2(1–603) in the absence (dark purple, solid line) and presence (light purple, dashed line) of 2 mM
Mg-AMPPNP. d,e Neuropathic mutations S87L and T424R alter the modes of ATP binding and dimerization of the ATPase module. d Structure of the ATP
lid (residues 82–103) of the S87L mutant. The structures of WT and S87L MORC2 dimers, bound to ATP and AMPPNP, respectively, were superimposed
using the ATPase module of one protomer as the alignment reference. Residues in the second protomer are labeled with asterisks; colored olive and gray
for S87L and WT, respectively. e Dimer interface near the site of SMA mutation T424R. The WT and T424R dimers were superimposed using both ATPase
modules of each dimer as the alignment reference. The WT and mutant protomers are colored and labeled as in panel c. f Model of MORC2 effector
function in HUSH silencing and its misregulation by neuropathic mutations S87L and T424R
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the ATPase module near the dimer interface, provides rotational
ﬂexibility to CC1. Since residues in each CC1 form hydrogen
bonds with the ATP lid and the other MORC2 protomer, ATP
binding and dimerization of the ATPase module may be coupled
to rotational motion of CC1, or to a change in the range of
rotational states accessible to CC1. Additional mechanisms of
coupling CC1 motions to ATP binding and dimerization may
operate in the context of full-length MORC2. A structure of
MORC2 in the absence of nucleotide is needed to shed further
light on the motions of CC1 and the inter-domain dynamics of
the system.
Despite similarities in the domain structure, several observa-
tions suggest that the mode of chromatin recruitment and
molecular functions of different MORCs vary across the family.
Firstly, MORC2 contains a tudor/chromo-like domain (TCD) not
found in other MORCs. The MORC2 TCD is dispensable for
effective HUSH function, suggesting that it is not required for
recruitment of MORC2 to HUSH loci4. However, MORC2 may
also be recruited to loci that are not HUSH targets4, and the TCD
may be involved in this. Secondly, the CW domains of MORC3
and MORC4 bind to H3K4me3, but the CW domains of MORC1
and MORC2 do not14. In the MORC2 structure, the degenerated
histone-binding surface of the CW domain binds to an array of
arginine residues in the ATPase module. Weakening these
interactions hyperactivates HUSH silencing implying that the
CW domain may have a regulatory function. Release of the CW
domain may transmit a functionally important motion through
the neighboring second coiled coil (CC2), the putative HUSH
binding module4, and could be triggered in WT MORC2 by
another protein or unidentiﬁed epigenetic mark. Alternatively,
the CW domain may function as a tandem reader (in concert
with the TCD) by contributing additional afﬁnity for a histone
tail despite possessing very low afﬁnity in isolation, as seen for
example in CHD139. Thirdly, sequence similarities between
MORC2 and MORC1 suggest that the two proteins have struc-
tural and functional similarities. MORC1 has a similar domain
structure to MORC2, including the CC1 insertion and a degen-
erated aromatic cage in the CW domain, lacking only the TCD.
Human MORC1 is expressed exclusively in the male germline
and the blastocyst, in which it silences active transposons at their
H3K4me3-marked transcriptional start sites (TSSs)5. MORC2 is
also found at TSSs in differentiated cells4. Notably, the CMT-
associated mutations R252W and D466N make the sequence of
MORC2 more homologous to that of MORC1. Since the R252W
MORC2 variant hyperactivates HUSH silencing, MORC1 may
have greater repressive activity than MORC2. This could be
advantageous because transposable elements are most actively
expressed in the germline and during early development, due to
the relief of epigenetic repression associated with the acquisition
of pluripotency in these cells.
MORC2 is the only gene in the MORC family in which
mutations have been reported to cause neuropathies in humans.
Here we have examined three disease mutations (S87L, R252W,
and T424R) that cause neuropathies diagnosed as CMT and/or
SMA. Our work provides insights on the basis of MORC2 mis-
regulation in affected patients and identiﬁes the link between the
biochemical activities of MORC2 and its cellular function as an
effector of HUSH. Modulation of putative HUSH-independent
activities of MORC2 may also be important in determining dis-
ease outcome. For example, MORC2 has been associated with the
activity of HDAC410, a protein known to be important in
synaptic plasticity and as a transcriptional regulator in the central
nervous system40, and which was overexpressed in SMA-model
mice and muscles of SMA patients41. More work will be needed
to understand how MORC2 mutations cause the range of clinical
symptoms described, but it is interesting to note that the muta-
tions causing pronounced changes in biochemical properties
(S87L, which causes constitutive N-terminal dimerization, and
T424R, which increases ATPase activity three-fold) are associated
with congenital or infantile onset, unlike the R252W mutation,
where the biochemical effect is more subtle and affected patients
presented later.
Based on our observed relationships between its in vitro and
in vivo activities, we conclude that MORC2 is part of a homeo-
static system tuned such that a reduction in biochemical activity
can cause a gain-of-function cellular phenotype, and vice versa.
Similarly, mutations in SMCHD1 cause BAMS, while others cause
facioscapulohumeral muscular dystrophy type 2 (FSHD2)24,25,
with varied effects on in vitro ATPase activity24. These studies
provide an interesting example in another GHKL ATPase of (i)
pleiotropic disease outcomes resulting from mutations in the
same gene, and (ii) gain of function cellular phenotypes resulting
from decreased biochemical activity and vice versa. Since both
gain and loss of MORC2 molecular function are linked to
Table 2 Summary of the molecular consequences of neuropathic and structure-based mutants of MORC2
Mutation Disease Activity relative to
wild-type MORC2
Position in structure Proposed mechanism of MORC2
misregulation
References
ATPase HUSH
Y18A — Higher No activity Dimer interface Does not dimerize This paper
N39A — No activity No activity Active site Cannot bind ATP This paper;4
S87L CMT/SMA Lower Higher ATP lid Constitutive N-terminal dimerization 16,21
R132La CMT nd nd ATPase core Destabilize ATPasea 21
E236Ga CMT nd nd ATPase core Destabilize ATPasea 17
R252W CMT Lower Higher ATPase–CW
interface
Destabilize ATPase-CW module 16,17,20,21,4
R266A — nd Higher ATPase–CW interface Destabilize ATPase-CW module This paper
R333Eb — nd No activity CC1 DNA binding & CC1 functional defect This paper
Q400Ra CMT nd nd ATPase core Destabilize ATPasea 18
T424R SMA Higher Lower Dimer interface Perturb dimerization dynamics 19,22
D466Na CMT nd nd ATPase surface Destabilize ATPasea 18,23
Shown in bold are those disease mutants that we have investigated in this paper
nd, not determined
aThese mutations have not been studied in this paper
bR333E is an example of several CC1 charge reversal mutants; see Fig. 3
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03045-x
12 NATURE COMMUNICATIONS |  (2018) 9:651 |DOI: 10.1038/s41467-018-03045-x |www.nature.com/naturecommunications
neuropathies, there are, in theory, a large number of MORC2
mutations that could cause disease including those that com-
promise the stability of the ATPase module. We would, therefore,
predict that there are other MORC2 mutations associated with
undiagnosed neuropathies. Here we have described a molecular
basis for understanding the MORC2 effector function in human
epigenetic silencing and the varied mechanisms of misregulation
that underlie MORC2-associated neuropathies.
Methods
Cell culture. Sf9 insect cells (Expression Systems) were grown in Insect-XPRESS
media (Lonza) with no antibiotics at 27 °C. HEK293T and HeLa cells (ECACC)
were grown in IMDM plus 10% FCS, GlutaMAX (1×) and penicillin/streptomycin
(100 UmL-1). The cell lines were routinely tested for mycoplasma contamination
using the MycoAlert detection kit (Lonza).
Protein expression and puriﬁcation. Human MORC2 (Uniprot Q9Y6X9–1;
residues 1–1032 and 1–603) were cloned by Gibson assembly into a modiﬁed
pOET transfer vector (Oxford Expression Technologies) for baculovirus-driven
production of N-terminally 3C protease-cleavable tandem-StrepII-tagged protein
(Supplementary Table 1). S. frugiperda (Sf9) cells were co-transfected with this
plasmid and linearized baculovirus genomic DNA (AB Vectors). Virus stocks were
ampliﬁed with three rounds of infection. For expression, Sf9 cells at a density of
2–2.5 × 106 cells per mL were infected with 2.5% (v/v) third-passage (P3) virus and
incubated with shaking at 27 °C for 50–60 h. All subsequent steps were performed
at 4 °C. The cells were harvested by centrifugation, resuspended in lysis buffer
containing 50 mM Tris, pH 8.0, 150 mM NaCl, 2 mM MgCl2, 1 mM DTT, 1:10,000
(v/v) benzonase solution (Sigma), 1× cOmplete EDTA-free protease inhibitors
(Roche), and ﬂash–frozen in liquid nitrogen before storage at −80 °C. Upon
thawing, the cells were lysed by sonication on ice. The ionic strength of the buffer
was then increased by adding NaCl from a 5M stock to a ﬁnal concentration of 0.5
M. The lysate was clariﬁed by centrifugation (1 h, 40,000× g). For a typical pre-
paration at a ~ 200-µg scale, the protein-containing supernatant was bound to 500
µL pre-equilibrated StrepTactin Sepharose High Performance resin (GE Health-
care) for 1 h. The sample was then applied to a 2-ml Pierce Centrifuge Column
(Thermo Scientiﬁc) and washed with at least 20 CV wash buffer (50 mM Tris, pH
8.0, 500 mM NaCl, 2 mM MgCl2, and 1 mM DTT) before elution with 5 mM d-
desthiobiotin in wash buffer. The buffer was exchanged to MORC2 gel ﬁltration
buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM MgCl2, and 0.25 mM TCEP)
with an Econo-Pac 10DG Desalting Column (Bio-Rad) and the tag cleaved by
overnight incubation with 10 U PreScission Protease (GE Healthcare). Alter-
natively, proteins were eluted from the resin with PreScission cleavage (40 U). The
GST-tagged protease was removed by incubating the cleaved sample twice with
100 µl glutathione agarose resin (Thermo Fisher Scientiﬁc). Final puriﬁcation was
achieved by SEC on a Superdex 200 increase (10/300) column (GE Healthcare).
Variants were expressed and puriﬁed in the same way as for wild-type (WT)
MORC2.
Human MORC2 (residues 1–282) was cloned into a pET15b vector for the
production of N-terminally His-tagged protein and expressed in E. coli BL21(DE3)
cells at 37 °C in 2xTY media containing 100 mg l−1 ampicillin. Expression was
induced at an OD600 of 0.8 with 0.2 mM IPTG for 18 h at 18 °C. The culture was
pelleted and resuspended in a buffer containing 50 mM Tris, pH 8.0, 500 mM
NaCl, 10 mM imidazole, 1 mM DTT, 1:10,000 (v/v) benzonase solution (Sigma),
and 1× cOmplete EDTA-free protease inhibitors (Roche), then ﬂash–frozen in
liquid nitrogen and stored at −80 °C. All subsequent steps were done at 4 °C.
Further lysis was achieved by extensive sonication (3 × 3 min). The lysate was
clariﬁed by centrifugation and the protein-containing supernatant was bound to
pre-equilibrated Ni-NTA beads (Generon) for 1 h. The beads were washed with at
least 20 CV Ni wash buffer (50 mM Tris, pH 8.0, 500 mM NaCl, 10 mM imidazole,
and 1 mM DTT) before a step-wise elution in batch mode with 3 × 5 CV of Ni wash
buffer supplemented with 200 mM, 300 mM, and 500 mM imidazole. Further
puriﬁcation was performed with size-exclusion chromatography on a Superdex 200
increase (10/300) column (GE Healthcare) in MORC2 gel ﬁltration buffer.
15N-labeled human MORC2 CW domain (residues 490–546) was expressed as a
His-SUMO-tagged fusion protein4 in M9 media containing 15NH4Cl (Sigma) as
the sole nitrogen source. Puriﬁcation was achieved by nickel afﬁnity
chromatography as described above, with the addition of 0.1 mM ZnSO4 in all
buffers, followed by tag cleavage with SENP-1 and SEC.
Limited proteolysis. Samples of 100 µl containing full-length MORC2 at ~0.1 mg
ml−1 in gel ﬁltration buffer were incubated with 1% (w/w) trypsin (Pierce) at room
temperature. Aliquots of 15 µl were removed at time intervals and the enzyme
quenched by adding 5 µl of 4 × SDS-PAGE-loading buffer and heating the sample
to 95 °C for 5 min. Samples of 10 µl were loaded on a NuPAGE 4–12% Bis-Tris gel
(Thermo Fisher Scientiﬁc) in MES running buffer, separated at 200 V for 45 min,
and then stained with Quick Coomassie stain (Generon).
Differential scanning ﬂuorimetry. Samples of 10 µl containing MORC2 variants
at 5 µM in the presence or absence of 2 mM AMPPNP or ADP/Pi (Sigma) were
prepared in gel ﬁltration buffer, incubated on ice for 1 h, and then loaded into glass
capillaries (Nanotemper) by capillary action. Intrinsic protein ﬂuorescence at 330
and 350 nm was monitored between 15 and 90 °C in the Prometheus NT.48
instrument (Nanotemper), and the Tm values calculated within the accompanying
software by taking the turning point of the ﬁrst derivative of the F350:F330 ratio as a
function of temperature. Nucleotide concentrations were determined spectro-
scopically using ε260 of 15.4 mM−1 cm−1.
Light scattering. Samples of 100 µL containing 0.5–3 mgml−1 MORC2(1–603)
variants were analyzed by SEC at 293 K using a Superdex 200 (10/300) column (GE
Healthcare) in gel-ﬁltration buffer with a ﬂow rate of 0.4 ml min−1. Where indi-
cated, 2 mM AMPPNP was added to the sample and incubated for 30 min on ice
before injection. The SEC system was coupled to both MALS and QELS modules
(Wyatt Technology). Light scattering analysis was performed in the ASTRA soft-
ware package, using band broadening parameters obtained from a BSA standard
run on the same day under identical conditions. MALS data were used to ﬁt the
average molar mass across the peak of interest (quoted to the nearest kDa) and
QELS data were used to ﬁt the hydrodynamic radii (Rh) of the species (quoted to
the nearest 0.1 nm).
ATP hydrolysis assays. Initial assessment of ATPase activity of MORC2 con-
structs was done with an ATPase/GTPase assay kit (Sigma) for detecting the release
of inorganic phosphate. Brieﬂy, MORC2 at a ﬁnal concentration of 3 µM was
mixed with assay buffer (Sigma) and ATP (Sigma) added to a ﬁnal concentration of
1 mM in a ﬂat-bottomed 96-well clear plate (Corning). After 90 min at room
temperature, the reaction was quenched with malachite green reagent and after a
further 10 min incubation, the absorbance at 620 nm was read with a Clariostar
plate reader (BMG LABTECH). For determining quantitative ATPase hydrolysis
rates in continuous mode, the NADH-coupled system27 was used to detect the
evolution of ADP in 384-well microplates (Corning) at 37 °C. Assays were set up in
a volume of 30 µL containing 0.35 mM NADH (VWR), 3 mM phosphoenolpyr-
uvate (VWR), 8 U lactate dehydrogenase (Roche), 2.5 U pyruvate kinase (Roche),
7.5 mM ATP (Sigma), and 1.6–4 µM MORC2 variants. The components (apart
from MORC2) were dissolved in an assay buffer containing 100 mM Tris, pH 8.0,
and 20 mM MgCl2. Blanks containing the protein buffer were included to account
for background NADH decomposition over the course of the experiment.
Pathlength-corrected NADH absorbance values at 340 nm were measured in a
Clariostar plate reader at 37 °C, at 1-min intervals over a period of 90 min. Linear
regression was used to ﬁt the rate of NADH consumption at steady state. Rates are
quoted as the consumption of NADH (µmol) per minute per µmol of MORC2,
using the extinction coefﬁcient ε340(NADH) of 6.22 mM−1cm−1. The rates were
blank-corrected and measured in triplicate. Non-linear regression analysis of Km
and Vmax was done in GraphPad Prism; values are quoted ± standard error. ATP
concentrations were determined spectroscopically using ε260 of 15.4 mM−1 cm−1.
X-ray crystallography. WT MORC2(1–603) was concentrated to 5 mgml−1 (~70
µM) and incubated with ten molar equivalents AMPPNP in MORC2 gel ﬁltration
buffer. Crystals were grown at 18 °C by the sitting drop vapor diffusion method, by
mixing the protein/nucleotide mixture at a 1:1 ratio with the reservoir solution
optimized from the Morpheus screen42: 0.1 M bicine/Trizma, pH 8.5, 9%
PEG4,000, 18% glycerol, and 0.12M Morpheus alcohols mix (Molecular Dimen-
sions) consisting of 0.02M each of 1,6-hexanediol, 1-butanol, (RS)-1,2 propanediol,
2-propanol, 1,4-butanediol, and 1,3-propanediol. Pyramidal crystals appeared in
1–2 days and were frozen in liquid N2 using 35% glycerol as a cryoprotectant. The
procedure was the same for the S87L and T424R variants except that the pre-
cipitant concentrations for the best crystals were higher (10–11% PEG4000 and
20–22% glycerol). In the case of the S87L variant, the protein was at 4.5 mg ml−1
and was concentrated from the earlier gel ﬁltration peak (i.e., the nucleotide-bound
dimeric fraction), which was assigned as ATP-bound; therefore, ATP was sup-
plemented in place of AMPPNP. X-ray diffraction data were collected at 100 K at
the European Synchrotron Radiation Facility (beamlines ID29 and ID30b) and
processed using the autoPROC package43. Molecular replacement was done with
Phaser44 using the mouse MORC3 ATPase (PDB: 5IX2) as a search model11 to
place the ATPase module. The Zn atoms and coordinating residues from the CW
domains were placed in real space, and the remainder built de novo in Coot45.
Models were iteratively reﬁned in Fourier space using REFMAC46 or PHENIX47.
The model building and real space reﬁnement were done in Coot. Crystallographic
data are summarized in Table 1. Structure ﬁgures were generated with PyMOL.
The radius of gyration of the wild-type structure was calculated in the HYDRO-
PRO software28. Portions of the ﬁnal reﬁned electron density maps are shown in
Supplementary Fig. 9.
Electrophoretic mobility shift assays. Samples of 10 μl containing 100 ng of 601
mononucleosome positioning sequence DNA (a kind gift from T. Bartke, Helm-
holtz Zentrum, Munich) or 500 nM NCP (a kind gift from S. Tan, Penn State
University) were incubated on ice with increasing concentrations of MORC2
variants in gel ﬁltration buffer for 1 h. The reaction mixtures were loaded on a 6%
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polyacrylamide gel that had been prerun on ice for 1 h at 150 V in 45 mM (0.5×)
Tris-borate buffer. Electrophoresis was performed at 150 V on ice for 90 min. The
gels were post-stained for DNA with 1× SYBR gold stain (Thermo Fisher Scien-
tiﬁc), then visualized with the G-BOX system (Syngene), or with 2 µM SYTO 62
(Invitrogen), and then visualized with the Odyssey CLx system (LICOR).
NMR spectroscopy. A volume of 550 μl containing 60 µM 15N-labeled MORC2
CW domain in a buffer containing 50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM
MgCl2, 0.5 mM TCEP, 0.1 mM ZnSO4, and 5% (v/v) D2O was transferred to a
5-mm NMR tube (Norell). Spectra were recorded at 293 K on a Bruker 600MHz
Avance III spectrometer and processed in Topspin software.
Flow cytometry. The cells were analyzed on a FACSFortessa (BD Biosciences)
instrument. Data were analyzed with FlowJo.
Antibodies. The following antibodies were used: mouse α-V5 (Abcam, ab27671,
1:5000 dilution), mouse α-β-actin (Sigma-Aldrich, A5316, 1:20,000 dilution), and
donkey α-mouse HRP-conjugated antibody (Jackson ImmunoResearch, 715-035-
150, 1:20,000 dilution). Validation of the antibodies is available online from the
manufacturers.
Immunoblotting. The cells were lysed in 1% SDS plus 1:100 (v/v) benzonase
solution (Sigma-Aldrich) for 15 min at room temperature, and then heated to 65 °C
in SDS sample loading buffer for 5 min. Following separation by SDS-PAGE, the
proteins were transferred to a PVDF membrane (Millipore), which was then
blocked in 5% milk in PBS + 0.2% Tween-20. The membranes were probed over-
night with the indicated primary antibodies, washed four times in PBS + 0.2%
Tween-20, then incubated with HRP-conjugated secondary antibodies for 1 h at
room temperature. Reactive bands were visualized using SuperSignal West Pico
(Thermo Fisher Scientiﬁc). Uncropped western blots are shown in Supplementary
Fig. 10.
Lentiviral expression. Exogenous gene expression in mammalian cells was per-
formed using the vector pHRSIN-PSFFV-V5-MORC2-IRES-mCherry-PPGK-Hygro4,
with the wild-type V5-MORC2 gene being replaced with the V5-MORC2 variant of
interest. The V5 tag included an SV40 nuclear localization signal with amino acid
sequence PKKKRKV. Lentivirus particles were generated through the triple
transfection of HEK293T cells with the lentiviral expression vector plus the two
packaging plasmids, pCMVΔR8.91 and pMD.G, by using TransIT-293 transfection
reagent (Mirus) according to the manufacturer’s recommendations. Viral super-
natant was typically harvested 48 h after transfection, cell debris was removed with
a 0.45-μm ﬁlter, and target cells were transduced by spin infection at 800× g for 60
min. The transduced HeLa cells were selected with hygromycin at 100 μg ml−1.
MORC2 complementation in MORC2-knockout cells. HeLa GFP MORC2 KO
reporter clones were transduced in triplicate with an appropriate volume of either
wild-type V5-MORC2 or a variant V5-MORC2 lentivirus, produced from the
pHRSIN-PSFFV-V5-MORC2-IRES-mCherry-PPGK-Hygro construct. Viral super-
natants were prepared, and cell transductions performed, as described above.
Forty-eight hours post-transduction, the cells were divided into replicate plates,
with one plate selected with 100 μg ml−1 hygromycin, and the other not. To con-
ﬁrm that the same level of transduction was achieved across all wells, the unselected
wells were FACS analyzed to determine the percentage of mCherry-positive cells
on day 5 post-transduction. The selected wells were maintained as required, and
were analyzed by FACS on the days indicated.
Statistics. No statistical methods were used to pre-determine the sample size,
experiments were not randomized, and the investigators were not blinded to
experimental outcomes. In all cases, ATPase activity data are represented as the
mean± s.d. of at least ﬁve replicates conducted across at least two independent
experiments (i.e., different protein preparations). EMSA gels and DSF data shown
are representative of at least two independent experiments. For the MORC2
complementation assays, data are representative of at least two independent
experiments and statistical signiﬁcance was assessed in GraphPad Prism.
Data availability. Crystal structures were deposited in the Protein Data Bank with
IDs 5OF9, 5OFA, and 5OFB. Raw crystallographic data were deposited with
SBGrid with data set numbers 457, 458, and 459. Other data are available from the
corresponding authors upon reasonable request.
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